Why Vera Therapeutics, Inc.’s (VERA) Stock Is Up 8.55%
As of Friday, August 14, Vera Therapeutics, Inc.’s VERA share price has surged by 8.55%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Commentary & Analysis
Why Vera Therapeutics, Inc.’s (VERA) Stock Is Down 5.82%
As of Tuesday, August 04, Vera Therapeutics, Inc.’s VERA share price has dipped by 5.82%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Vera Therapeutics, Inc.’s (VERA) Stock Is Down 6.37%
As of Tuesday, July 28, Vera Therapeutics, Inc.’s VERA share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Vera Therapeutics, Inc.’s (VERA) Stock Is Down 5.11%
As of Thursday, July 16, Vera Therapeutics, Inc.’s VERA share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Vera Therapeutics, Inc.’s (VERA) Stock Is Down 7.14%
As of Friday, July 10, Vera Therapeutics, Inc.’s VERA share price has dipped by 7.14%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | VERA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,252.7 | $286.3 | 55% |
|
| Shares Out (Mil) | 71.8 | 54.2 | 55% |
|
| Institutional Ownership | 99.0% | 92.8% | 84% |
|
| Float (Mil) | 52.4 | 39.7 | 48% |
|
| Beta | 0.95 | 0.94 | 57% |
|
| Avg Daily Volume (000s) | 1,976 | 534 | 82% |
|
| Price Change (52-week) |
41.6% | 58.7% | 75% |
|
| Growth | VERA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (41.2%) | (10.1%) | 9% |
|
| EPS (5yr) | 51.1% | 16.0% | 93 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (51.8%) | (15.6%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | ($1.644) | ($6.322) | ($4.414) | |
| Month Ago EPS | ($1.543) | ($6.209) | ($3.859) | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($1.634) | ($6.207) | ($3.540) | |
| Year/Year Chg | 7.9% | 35.5% | (81.6%) | |
| Financials | VERA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($402) | ($43) | 4% |
|
| EPS (TTM) | ($5.893) | ($1.400) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($339) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $2 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $77 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,761 | $160 | 47% |
|
| Valuation | VERA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.51 | 2.77 | 80% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VERA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (72.3%) | (47.3%) | 8% |
|
| ROE | (91.8%) | (55.0%) | 10% |
|
| Liabilities to Assets | 23.5% | 29.6% | 16% |
|
| F-Score | 2 | 2 | 7% |
|
Vera Therapeutics, Inc. did not pass any screens on 8/20/2026.
